Nasdaq
$9.76▲ 0.00%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $577.6MShares out 59.2M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
4- 9.30Pre-market26.09.30 10:18filed8-KKey event#●●●#●●●
DBV Technologies S.A.Bullish
DBV Technologies has submitted a Biologics License Application (BLA) to the U.S. FDA for its VIASKIN Peanut Patch, intended for children aged 4 to 7 with peanut allergies. The application is supported by positive results from the Phase 3 VITESSE trial involving 654 participants, and the company has requested Priority Review status.…more
$9.76+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 8.6After-hours26.08.07 06:50SCHEDULE 13GOwnership
DBV Technologies S.A.
RA Capital Management, L.P.와 Peter Kolchinsky, Rajeev Shah 등 주요 투자자들이 DBV Technologies S.A.의 지분 보유 현황을 공동으로 공시하기 위한 합의서를 2026년 8월 6일 체결했다. 이번 합의에 따라 해당 투자자들은 향후 DBV Technologies의 보통주 보유와 관련된 Schedule 13G 및 13D 보고서를 공동으로 제출하게 된다.…more
$9.76+0.00%vs prev closeView filingShare - 7.31After-hours26.08.01 05:154Ownership
DBV Technologies S.A.
DBV Technologies S.A.의 내부자인 모히딘 파리스(Mohideen Pharis)가 2026년 7월 29일 자로 주식 소유 현황 변경을 보고하는 Form 4를 제출했습니다. 본 공시는 내부자의 지분 변동 사항을 공식적으로 기록한 것으로, 회사의 지배구조 및 내부자 거래 동향을 나타냅니다.…more
$9.76+0.00%vs prev closeView filingShare
3 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.30Overnight26.09.30 16:43#●●●#●●●#●●●
DBV Technologies Submits BLA to FDA for Viaskin Peanut Patch
DBV Technologies has submitted a Biologics License Application to the FDA for its Viaskin Peanut patch targeting children aged 4-7. The company has requested priority review based on successful Phase 3 clinical trial results.…more
$9.76+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 9.29After-hours26.09.30 07:29
●●●●●●●● ●●●●● ●●●●●●
DBV Technologies has submitted a Biologics License Application to the U.S. FDA for its VIASKIN Peanut Patch targeting children aged 4-7. The application is supported by positive Phase 3 trial results and includes a request for Priority Review.…more
$9.76+0.00%vs prev close - 9.3After-hours26.09.04 05:32
●●●●●●●● ●●●●● ●●●●●●
DBV Technologies announced its participation in several healthcare investor conferences scheduled for September. This announcement is a routine corporate update and does not contain material information affecting the stock price.…more
$9.76+0.00%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report